Program
Topotecan
Also written as “topotecan”, “topotecan hydrochloride” and “Topotecan/Docetaxel combination”.
Its studies are mostly in Small Cell Lung Carcinoma · Ovarian Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms, led by 15 companies.
Drug pageTopotecan: every studyMany companies study it; this page follows only the 33 they lead. All 251 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 180 open or running | phase 3since Aug 14, 2002 | Nov 2, 1999 | none ahead |
| Bristol-Myers Squibbits history only | 20 open or running | phase 2since Sep 10, 2005 | Sep 10, 2005 | none ahead |
| AbbVieits history only | 10 open or running | phase 3since Dec 10, 2015 | Dec 10, 2015 | none ahead |
| Advenchen Laboratoriesits history only | 11 open or running | phase 3since Aug 28, 2015 | Aug 28, 2015 | none ahead |
| Ascenta Therapeuticsits history only | 10 open or running | phase 2since Nov 7, 2006 | Nov 7, 2006 | none ahead |
| AstraZenecaits history only | 10 open or running | phase 2since Apr 10, 2001 | Apr 10, 2001 | none ahead |
| BioNTechits history only | 11 open or running | phase 2since Jun 3, 2024 | Jun 3, 2024 | Jun 2027phase 2 · NCT06449209 |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 2since Mar 6, 2012 | Mar 6, 2012 | none ahead |
| Gilead Sciencesits history only | 11 open or running | phase 3since Jan 24, 2025 | Jan 24, 2025 | Oct 2029phase 3 · NCT06801834 |
| Hoffmann-La Rocheits history only | 10 open or running | phase 3since Sep 11, 2012 | Sep 11, 2012 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Novartisits history only | 10 open or running | phase 1since Jun 17, 2022 | Jun 17, 2022 | none ahead |
| Pfizerits history only | 10 open or running | phase 2since Oct 9, 2018 | Oct 9, 2018 | none ahead |
| Sichuan Biokin Pharmaceuticalits history only | 11 open or running | phase 3since Jul 8, 2024 | Jul 8, 2024 | Dec 2026phase 3 · NCT06500026 |
| SynerGene Therapeuticsits history only | 10 open or running | phase 1since Dec 18, 2014 | Dec 18, 2014 | none ahead |
Also a collaborator on its studies: Eisai, Baili-Bio (Chengdu) Pharmaceutical and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Nov 2, 1999.
- Nov 18, 2002Phase 3 study in Carcinoma, Non-Small-Cell LungNCT00049998 · 760 enrolled · Australia, Austria, Belgium and more
- May 23, 2003Phase 2 study in Ovarian NeoplasmsNCT00061308 · 75 enrolled · United States, Canada
- Jul 17, 2003Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00065182 · 399 enrolled · United States, Canada, Poland
- Sep 8, 2005Phase 1 study in Carcinoma, Renal CellNCT00158886 · 26 enrolled · United States
- Nov 30, 2005Phase 1 study in Small Cell Lung CarcinomaNCT00259935 · 107 enrolled · United States, Netherlands
- Dec 20, 2005Phase 2 study in Endometrial NeoplasmsNCT00267488 · 70 enrolled · United States, Canada, Hungary
- Jan 11, 2006Phase 3 study in Small Cell Lung CarcinomaNCT00276276 · 141 enrolled · Bulgaria, Hungary, Netherlands and more
- May 1, 2006Phase 3 study in Small Cell Lung CarcinomaNCT00320359 · 700 enrolled · Austria, Germany
- Aug 7, 2006Phase 1 study in NeoplasmsNCT00361803 · 15 enrolled · United States
- Oct 19, 2006Phase 3 study in Carcinoma, Non-Small-Cell LungNCT00390806 · 472 enrolled · United States, Canada, Hungary and more
- Feb 15, 2007Phase 2 study in Breast NeoplasmsNCT00437073 · 22 enrolled · United States, Austria, Belgium and more
- Jun 5, 2007Phase 1 study in NeoplasmsNCT00483860 · 59 enrolled · United States, Korea, Republic of, Netherlands
- Jun 16, 2008Phase 2 study in Small Cell Lung CarcinomaNCT00698516 · 50 enrolled · United States
- Aug 11, 2008Phase 1 study in Solid TumoursNCT00732420 · 68 enrolled · United States, Netherlands
TargetBeta
“DNA topoisomerase I inhibitor”ChEMBL 37, by rule
Other programs on TOP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| irinotecan sucrosofaterule | CSPC Pharmaceutical Group | phase 3 | 20 |
Studies
All 18 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00732420Solid Tumours · United States, Netherlands | 1 | Completed | Jun 12, 2013 | 68 |
| NCT00698516Small Cell Lung Carcinoma · United States | 2 | Completed | May 2010 | 50 |
| NCT00483860Neoplasms · United States, Korea, Republic of, Netherlands | 1 | Completed | Feb 6, 2012 | 59 |
| NCT00437073Breast Neoplasms · United States, Austria, Belgium and more | 2 | Terminated | Jan 2009 | 22 |
| NCT00390806Carcinoma, Non-Small-Cell Lung · United States, Canada, Hungary and more | 3 | Completed | Jul 2012 | 472 |
| NCT00361803Neoplasms · United States | 1 | Completed | Aug 9, 2007 | 15 |
| NCT00320359Small Cell Lung Carcinoma · Austria, Germany | 3 | Completed | Feb 2007 | 700 |
| NCT00276276Small Cell Lung Carcinoma · Bulgaria, Hungary, Netherlands and more | 3 | Completed | 141 | |
| NCT00267488Endometrial Neoplasms · United States, Canada, Hungary | 2 | Completed | Dec 2007 | 70 |
| NCT00259935Small Cell Lung Carcinoma · United States, Netherlands | 1 | Completed | Jul 5, 2007 | 107 |
| NCT00158886Carcinoma, Renal Cell · United States | 1 | Terminated | Aug 11, 2006 | 26 |
| NCT00065182Carcinoma, Non-Small-Cell Lung · United States, Canada, Poland | 2 | Completed | Aug 30, 2007 | 399 |
| NCT00061308Ovarian Neoplasms · United States, Canada | 2 | Completed | Sep 2004 | 75 |
| NCT00049998Carcinoma, Non-Small-Cell Lung · Australia, Austria, Belgium and more | 3 | Completed | Apr 2004 | 760 |
| NCT00046111Small Cell Lung Carcinoma · United States, Canada | 1 | Completed | Apr 2004 | 1 |
| NCT00043927Small Cell Lung Carcinoma · United States, Austria, Belgium and more | 3 | Completed | Jan 2004 | 760 |
| NCT00043862Small Cell Lung Carcinoma · United States | 2 | Completed | Nov 2005 | 60 |
| NCT00002395HIV Infections · United States | 2 | Completed | 54 |
How it is read
Names in the registry
- “Topotecan”, 15 entries
- “topotecan”, 11 entries
- “topotecan hydrochloride”, 2 entries
- “Topotecan/Docetaxel combination”, 1 entry
- “Topotecan (Chemotherapy)”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 11 studies
- Ovarian Neoplasms, 4 studies
- Neoplasms, 3 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Endometrial Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.